Dr. Spratt on the importance of a multidisciplinary approach to PSMA-PET
“I think that having the clinical context such as the PSA, the Gleason score, the other features that assess the aggressiveness of the disease can really help with some of these subtle findings that can be found on PET imaging,” says Daniel Spratt, MD.
EP: 1.Harnessing the Full Power of PSMA-PET Requires Multidisciplinary Approach
EP: 2.Dr. Spratt on the importance of a multidisciplinary approach to PSMA-PET
EP: 3.PSMA-PET leads imaging breakthroughs in prostate cancer paradigm
EP: 4.Conventional imaging obstacles that PSMA-PET overcomes
EP: 5.Dr. Sohi on the timing of PSMA-PET imaging in prostate cancer
EP: 6.Dr. Sohi on why PSMA-PET results can alter treatment plans
In this video, Daniel Spratt, MD, discusses the critical need for a multidisciplinary approach to PSMA-PET in order to harness the full potential of the breakthrough. Spratt is the chairman and professor of radiation oncology at University Hospitals Seidman Cancer Center and Case Western Reserve University in Cleveland, Ohio.
Video Transcript:
With any new treatment technology, and imaging falls right into that category, there's a big learning curve, both for the radiologist or nuclear medicine physicians to interpret and read and understand that imaging, but often, it really requires a multidisciplinary approach with the clinicians, with the surgeons or radiation oncologists or medical oncologists, because there are some unique false positives with this PSMA-PET imaging. One of the most common that we discuss a lot in our clinics is there can be subtle uptake in ribs. It's been pretty well established that most of these appear to be false positives. That low SUV uptake does not translate into these actually being metastatic sites. But if you call these as metastases, you would be giving potentially doublet or maybe, depending on other features, triplet systemic therapy, vs maybe just offering local therapy to the patient. I think that having the clinical context such as the PSA, the Gleason score, the other features that assess the aggressiveness of the disease can really help with some of these subtle findings that can be found on PET imaging.
This transcription has been edited for clarity.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.
